Nailrox® Cream 20g/0.7oz

The Biologics Business Unit (BU) of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as Intas Biopharmaceuticals Ltd. Intas Pharmaceuticals Limited is an Indian company headquartered in Ahmedabad, India. The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading biosimilar product manufacturers in Asia. Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company headquartered in India. Intas' success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R&D, Biotechnology and global operations over three decades. As on 31st of March 2018, Intas has recorded a global turnover of $1.7 billion at >20% CAGR over the last 5 years. Intas is currently ranked 11th in the Indian Pharma Market with 2.9% market share*. In the domestic market, Intas enjoys a leadership position in chronic therapies such as Neurology, Psychiatry, Cardiovascular, Diabetes, Oncology, Urology, Nephrology, Rheumatology & Gynecology, Infertility, Gastroenterology, Pain Management and healthy presence in other major therapeutic segments. Besides well-established domestic prominence, Intas is also present in more than 80 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, Asia-Pacific as well as CIS and MENA countries. Intas' global strategy includes alliances with leading Global Pharma Companies for the development and distribution of products as well as direct product distribution. The company is known for its range of products in Oncology and other hospital-based therapeutic segments in the EU and US. After the landmark acquisition of Teva's assets, Intas has become a leading player in the generics market in the UK. Intas' success and growth is a direct influence of Intas' extensive R&D capabilities, its manufacturing abilities, and its people. Every year, the company invests around 6-7% of its revenues in R&D. Besides building the regular portfolio of generic products, Intas' R&D is also focused on creating a pipeline of novel drug delivery technology-based products and biologics and has invested over $125 million to develop and enhance its biosimilar capabilities over the past 8 years. Intas operates fourteen formulation manufacturing facilities, of which seven are located in India, and the rest in the U.K. and Mexico. Two of their flagship facilities are accredited by top global regulators such as USFDA, EMA, MHRA, TGA, etc. It is also the first company in India to have its biologics manufacturing facility accredited by the European Health Authority. Intas operates sixteen formulation manufacturing facilities, of which eleven are located in India, and the rest in the U.K. and Mexico. It also operates two API and intermediate manufacturing facilities, each of which complies with the regulatory requirements in the jurisdictions in which it operates. Between them, these facilities have received approvals from various prominent international regulatory bodies, including from U.S. Food and Drug Administration (FDA). Each of Intas' manufacturing facilities is designed, equipped and operated to deliver high-quality products within defined cost and delivery schedules. These manufacturing facilities have the flexibility to operate in various dosage forms and a wide range of batch sizes. Intas' world class oncology formulation facility operates under global regulatory and safety standards. The Ahmedabad SEZ caters exclusively to the US, Europe and other regulated markets. A highly advanced upcoming facility in Ahmedabad, Gujarat is set to double Intas' manufacturing capabilities.